Review: Glutamate and dopamine dysregulation in schizophrenia — a synthesis and selective review

The dopamine hypothesis of schizophrenia is the principal explanatory model of antipsychotic drug action. Recent discoveries extend our understanding of the neurochemistry of schizophrenia, with increasing evidence of dysfunction in glutamate and GABA as well as dopamine systems. In this review, we study the evidence for dopaminergic dysfunction in schizophrenia, drawing data from neurochemical imaging studies. We also review the NMDA receptor hypofunction hypothesis of schizophrenia as a supplementary explanatory model for the illness. We examine predictions made by the NMDA receptor hypofunction hypothesis and consider how they fit with current neurochemical findings in patients and animal models. We consider the case for glutamatergic excitotoxicity as a key process in the development and progression of schizophrenia, and suggest ways in which glutamate and dopamine dysregulation may interact in the condition.

[1]  D. Lodge,et al.  The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N‐methyl‐aspartate , 1983, British journal of pharmacology.

[2]  R. Kerwin,et al.  Striatal and extra-striatal D(2)/D(3) dopamine receptor occupancy by quetiapine in vivo. [(123)I]-epidepride single photon emission tomography(SPET) study. , 2000, The British journal of psychiatry : the journal of mental science.

[3]  G. Rosenbaum,et al.  Study of a new schizophrenomimetic drug; sernyl. , 1959, A.M.A. archives of neurology and psychiatry.

[4]  C. Marsden,et al.  Changes in rat striatal dopamine turnover and receptor activity during one years neuroleptic administration. , 1980, European journal of pharmacology.

[5]  Ravi S. Menon,et al.  Glutamate and glutamine in the anterior cingulate and thalamus of medicated patients with chronic schizophrenia and healthy comparison subjects measured with 4.0-T proton MRS. , 2003, The American journal of psychiatry.

[6]  K. Erlandsson,et al.  Non-uniform blockade of intrastriatal D2/D3 receptors by risperidone and amisulpride , 2005, Psychopharmacology.

[7]  T. Crow,et al.  CEREBRAL VENTRICULAR SIZE AND COGNITIVE IMPAIRMENT IN CHRONIC SCHIZOPHRENIA , 1976, The Lancet.

[8]  Karin E. Borgmann-Winter,et al.  Altered neuregulin 1–erbB4 signaling contributes to NMDA> receptor hypofunction in schizophrenia , 2006, Nature Medicine.

[9]  E. Kandel,et al.  Genetic evidence for the bidirectional modulation of synaptic plasticity in the prefrontal cortex by D1 receptors. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[10]  H. Moore,et al.  Prefrontal DA Transmission at D1 Receptors and the Pathology of Schizophrenia , 2003, The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry.

[11]  R. Roth,et al.  The Neuropsychopharmacology of Phencyclidine: From NMDA Receptor Hypofunction to the Dopamine Hypothesis of Schizophrenia , 1999, Neuropsychopharmacology.

[12]  A. Belger,et al.  Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitive function. , 2005, Archives of general psychiatry.

[13]  Paul J. Harrison The neuropathology of schizophrenia , 2008 .

[14]  P. Calabresi,et al.  Endogenous ACh enhances striatal NMDA‐responses via M1‐like muscarinic receptors and PKC activation , 1998, The European journal of neuroscience.

[15]  M. Boekel,et al.  Kinetic modelling , 2022 .

[16]  K. Jellinger,et al.  DOPAMINE RECEPTORS AND SCHIZOPHRENIA: DRUG EFFECT OR ILLNESS , 1980, The Lancet.

[17]  H. Lehmann,et al.  Observations on the Action of Sernyl — A New Psychotropic Drug , 1961, Canadian Psychiatric Association journal.

[18]  John H. Gilmore,et al.  Apoptotic mechanisms and the synaptic pathology of schizophrenia , 2006, Schizophrenia Research.

[19]  L. Mallet,et al.  Extrastriatal and striatal D2 dopamine receptor blockade with haloperidol or new antipsychotic drugs in patients with schizophrenia , 2001, British Journal of Psychiatry.

[20]  Alan A. Wilson,et al.  Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypical antipsychotics. , 2004, The American journal of psychiatry.

[21]  J. Libiger,et al.  Antiepileptic drugs in schizophrenia: a review , 2002, European Psychiatry.

[22]  Kevin T. Hansen,et al.  Dopamine D2 densities and the schizophrenic brain , 1998, Schizophrenia Research.

[23]  D. Malone,et al.  Comparison of chlorpromazine, haloperidol and pimozide in the treatment of phencyclidine psychosis: DA-2 receptor specificity. , 1984, Journal of toxicology. Clinical toxicology.

[24]  J. Krystal,et al.  First in vivo evidence of an NMDA receptor deficit in medication-free schizophrenic patients , 2006, Molecular Psychiatry.

[25]  R. Murray,et al.  D2 Dopamine Receptor Binding in the Basal Ganglia of Antipsychotic-Free Schizophrenic Patients , 1994, British Journal of Psychiatry.

[26]  R. Rosenheck,et al.  Impact of clozapine on negative symptoms and on the deficit syndrome in refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. , 1999, The American journal of psychiatry.

[27]  J. Newcomer,et al.  NMDA receptor hypofunction model of schizophrenia. , 1999, Journal of psychiatric research.

[28]  J. Krystal,et al.  Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[29]  J. Olney,et al.  Glutamate receptor dysfunction and schizophrenia. , 1995, Archives of general psychiatry.

[30]  Yasuhiro Kaneda,et al.  Serotonin receptors : their key role in drugs to treat schizophrenia , 2003, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[31]  S. Grimwood,et al.  Modulation of [3H]MK-801 binding to NMDA receptors in vivo and in vitro. , 2000, European journal of pharmacology.

[32]  R. Tandon Cholinergic aspects of schizophrenia , 1999, British Journal of Psychiatry.

[33]  S. Stone-Elander,et al.  D2 dopamine receptors in neuroleptic-naive schizophrenic patients. A positron emission tomography study with [11C]raclopride. , 1990, Archives of general psychiatry.

[34]  D Hell,et al.  Effects of (S)-ketamine on striatal dopamine: a [11C]raclopride PET study of a model psychosis in humans. , 2000, Journal of psychiatric research.

[35]  H. Beech,et al.  The effect of 1-arylcylohexylamine (sernyl) on twelve normal volunteers. , 1960, The Journal of mental science.

[36]  C. Bakker,et al.  Observations on the psychotomimetic effects of Sernyl. , 1961, Comprehensive psychiatry.

[37]  H. Tanila,et al.  Cortical glutamate–dopamine interaction and ketamine-induced psychotic symptoms in man , 2005, Psychopharmacology.

[38]  S. Snyder,et al.  Properties of [3H]haloperidol and [3H]dopamine binding associated with dopamine receptors in calf brain membranes. , 1976, Molecular pharmacology.

[39]  M. Laruelle Imaging dopamine transmission in schizophrenia. A review and meta-analysis. , 1998, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.

[40]  S. Kapur,et al.  NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D2 and serotonin 5-HT2 receptors—implications for models of schizophrenia , 2002, Molecular Psychiatry.

[41]  G Honigfeld,et al.  Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. , 1988, Archives of general psychiatry.

[42]  P Riederer,et al.  Bimodal distribution of dopamine receptor densities in brains of schizophrenics. , 1984, Science.

[43]  L. Siever,et al.  Striatal amphetamine-induced dopamine release in patients with schizotypal personality disorder studied with single photon emission computed tomography and [123I]iodobenzamide , 2004, Biological Psychiatry.

[44]  P. Kalus,et al.  The dendritic architecture of prefrontal pyramidal neurons in schizophrenic patients , 2000, Neuroreport.

[45]  D. Doudet,et al.  6-18F-DOPA PET study in patients with schizophrenia , 2000, Psychiatry Research: Neuroimaging.

[46]  R. Conley,et al.  Ionotropic glutamate receptors and expression of N-methyl-D-aspartate receptor subunits in subregions of human hippocampus: effects of schizophrenia. , 2000, The American journal of psychiatry.

[47]  A. Becker,et al.  Repeated application of ketamine to rats induces changes in the hippocampal expression of parvalbumin, neuronal nitric oxide synthase and cFOS similar to those found in human schizophrenia , 2004, Neuroscience.

[48]  P. Somogyi,et al.  Synchronization of neuronal activity in hippocampus by individual GABAergic interneurons , 1995, Nature.

[49]  B. Lipska CRSN Symposium: Focus on Schizophrenia Symposium du CRSN : le point sur la schizophrénie Using animal models to test a neurodevelopmental hypothesis of schizophrenia , 2004 .

[50]  Roger N Gunn,et al.  A bolus/infusion paradigm for the novel NMDA receptor SPET tracer [123I]CNS 1261. , 2004, Nuclear medicine and biology.

[51]  Eve C. Johnstone,et al.  Grey matter changes over time in high risk subjects developing schizophrenia , 2005, NeuroImage.

[52]  Philip Seeman,et al.  Atypical Antipsychotics: Mechanism of Action , 2002, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[53]  G. Rosoklija,et al.  Structural abnormalities of subicular dendrites in subjects with schizophrenia and mood disorders: preliminary findings. , 2000, Archives of general psychiatry.

[54]  J. Gold,et al.  The role of negative symptoms and cognitive dysfunction in schizophrenia outcome , 1998, International clinical psychopharmacology.

[55]  Peter J Ell,et al.  Limbic selectivity of clozapine , 1997, The Lancet.

[56]  D. Javitt Is the glycine site half saturated or half unsaturated? Effects of glutamatergic drugs in schizophrenia patients , 2006, Current opinion in psychiatry.

[57]  L. DeLisi,et al.  Ten year longitudinal study of neuropsychological functioning subsequent to a first episode of schizophrenia , 2005, Schizophrenia Research.

[58]  C. Reutelingsperger,et al.  Past, present, and future of annexin A5: from protein discovery to clinical applications. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[59]  Hideo Tsukada,et al.  Chronic NMDA Antagonism Impairs Working Memory, Decreases Extracellular Dopamine, and Increases D1 Receptor Binding in Prefrontal Cortex of Conscious Monkeys , 2005, Neuropsychopharmacology.

[60]  R. McCarley,et al.  A review of MRI findings in schizophrenia , 2001, Schizophrenia Research.

[61]  J. Lieberman,et al.  Apoptotic mechanisms in the pathophysiology of schizophrenia , 2005, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[62]  H. Meltzer,et al.  N-Desmethylclozapine, a Major Metabolite of Clozapine, Increases Cortical Acetylcholine and Dopamine Release In Vivo Via Stimulation of M1 Muscarinic Receptors , 2005, Neuropsychopharmacology.

[63]  A. Guidotti,et al.  GABAergic dysfunction in schizophrenia: new treatment strategies on the horizon , 2005, Psychopharmacology.

[64]  Marc Ansseau,et al.  Dopamine–glutamate reciprocal modulation of release and motor responses in the rat caudate–putamen and nucleus accumbens of “intact” animals , 2005, Brain Research Reviews.

[65]  M Laruelle,et al.  Alterations of benzodiazepine receptors in type II alcoholic subjects measured with SPECT and [123I]iomazenil. , 1998, The American journal of psychiatry.

[66]  J. Meador-Woodruff,et al.  Glutamate receptor expression in schizophrenic brain , 2000, Brain Research Reviews.

[67]  B. Moghaddam,et al.  Corticolimbic Dopamine Neurotransmission Is Temporally Dissociated from the Cognitive and Locomotor Effects of Phencyclidine , 1998, The Journal of Neuroscience.

[68]  R. Gunn,et al.  Kinetic modelling of [123I]CNS 1261--a potential SPET tracer for the NMDA receptor. , 2003, Nuclear medicine and biology.

[69]  Sooyoung Chung,et al.  Maternal Stress Produces Learning Deficits Associated with Impairment of NMDA Receptor-Mediated Synaptic Plasticity , 2006, The Journal of Neuroscience.

[70]  J. Olney,et al.  Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain. , 1999, Science.

[71]  R. Murray,et al.  Is schizophrenia a neurodevelopmental disorder? , 1987, British medical journal.

[72]  B. Mazoyer,et al.  The Estimated Density of D2 Striatal Receptors in Schizophrenia , 1991, British Journal of Psychiatry.

[73]  P. Seeman,et al.  Brain receptors for antipsychotic drugs and dopamine: direct binding assays. , 1975, Proceedings of the National Academy of Sciences of the United States of America.

[74]  N. Uranova,et al.  Ultrastructural alterations in hippocampal mossy fiber synapses in schizophrenia: A postmortem morphometric study , 2005, Synapse.

[75]  R. Parsey,et al.  Dopamine D2 receptor availability and amphetamine-induced dopamine release in unipolar depression , 2001, Biological Psychiatry.

[76]  J. Lauriello,et al.  Effects of ketamine on anterior cingulate glutamate metabolism in healthy humans: a 4-T proton MRS study. , 2005, The American journal of psychiatry.

[77]  Philip Seeman,et al.  Dopamine supersensitivity correlates with D2High states, implying many paths to psychosis. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[78]  N. Volkow,et al.  Glutamate Modulation of Dopamine Measured in Vivo with Positron Emission Tomography (PET) and 11C-Raclopride in Normal Human Subjects , 1998, Neuropsychopharmacology.

[79]  M. Laruelle,et al.  Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia , 2000, Biological Psychiatry.

[80]  S. Haber,et al.  The interface between dopamine neurons and the amygdala: implications for schizophrenia. , 1997, Schizophrenia bulletin.

[81]  D. Goff,et al.  Converging Evidence of NMDA Receptor Hypofunction in the Pathophysiology of Schizophrenia , 2003, Annals of the New York Academy of Sciences.

[82]  J. Krystal,et al.  Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. , 1994, Archives of general psychiatry.

[83]  Bita Moghaddam,et al.  Activation of Glutamatergic Neurotransmission by Ketamine: A Novel Step in the Pathway from NMDA Receptor Blockade to Dopaminergic and Cognitive Disruptions Associated with the Prefrontal Cortex , 1997, The Journal of Neuroscience.

[84]  B. Morris,et al.  Induction of Metabolic Hypofunction and Neurochemical Deficits after Chronic Intermittent Exposure to Phencyclidine: Differential Modulation by Antipsychotic Drugs , 2003, Neuropsychopharmacology.

[85]  J. Deakin,et al.  Asymmetrical reductions of hippocampal NMDAR1 glutamate receptor mRNA in the psychoses , 2001, Neuroreport.

[86]  B. Pakkenberg,et al.  The volume of the mediodorsal thalamic nucleus in treated and untreated schizophrenics , 1992, Schizophrenia Research.

[87]  S. Siris,et al.  Implications of normal brain development for the pathogenesis of schizophrenia. , 1988, Archives of general psychiatry.

[88]  M. Poulter,et al.  INCREASED DOPAMINE-RECEPTOR SENSITIVITY IN SCHIZOPHRENIA , 1978, The Lancet.

[89]  A. Malhotra,et al.  Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[90]  R. Mckernan,et al.  Generation and Characterisation of Stable Cell Lines Expressing Recombinant Human N‐Methyl‐d‐Aspartate Receptor Subtypes , 1996, Journal of neurochemistry.

[91]  Hans-Georg Buchholz,et al.  The Striatal and Extrastriatal D2/D3 Receptor-Binding Profile of Clozapine in Patients with Schizophrenia , 2006, Neuropsychopharmacology.

[92]  R. Behrendt Dysregulation of thalamic sensory ‘transmission’ in schizophrenia: neurochemical vulnerability to hallucinations , 2006, Journal of psychopharmacology.

[93]  L. Iversen,et al.  Dopaminergic abnormalities in postmortem schizophrenic brain. , 1980, Advances in biochemical psychopharmacology.

[94]  G. Reynolds,et al.  Calcium binding protein markers of GABA deficits in schizophrenia--postmortem studies and animal models. , 2004, Neurotoxicity research.

[95]  Gähwiler Alterations in dendritic morphology induced by lesions, chemical deafferentation and epileptiform activity. , 1999, Acta physiologica Scandinavica.

[96]  G. Reynolds,et al.  Calcium binding protein markers of GABA deficits in schizophrenia — post mortem studies and animal models , 2009, Neurotoxicity Research.

[97]  Douglas W. Jones,et al.  In vivo determination of muscarinic acetylcholine receptor availability in schizophrenia. , 2003, The American journal of psychiatry.

[98]  D. Lewis,et al.  Cortical inhibitory neurons and schizophrenia , 2005, Nature Reviews Neuroscience.

[99]  R. Tandon,et al.  Covariance of positive and negative symptoms during neuroleptic treatment in schizophrenia: A replication , 1993, Biological Psychiatry.

[100]  N. Andreasen A unitary model of schizophrenia: Bleuler's "fragmented phrene" as schizencephaly. , 1999, Archives of general psychiatry.

[101]  K. Erlandsson,et al.  Is regionally selective D2/D3 dopamine occupancy sufficient for atypical antipsychotic effect? an in vivo quantitative [123I]epidepride SPET study of amisulpride-treated patients. , 2003, The American journal of psychiatry.

[102]  J. Tiihonen,et al.  Topiramate add-on in treatment-resistant schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial. , 2005, The Journal of clinical psychiatry.

[103]  Myriam Bernaudin,et al.  Psychosis: pathological activation of limbic thalamocortical circuits by psychomimetics and schizophrenia? , 2001, Trends in Neurosciences.

[104]  S. Leucht,et al.  New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis , 2003, The Lancet.

[105]  J. Hietala,et al.  Depressive symptoms and presynaptic dopamine function in neuroleptic-naive schizophrenia , 1999, Schizophrenia Research.

[106]  S. Deutsch,et al.  Topiramate antagonizes MK-801 in an animal model of schizophrenia. , 2002, European journal of pharmacology.

[107]  R Kono,et al.  Antibody titres to enterovirus type 70 in the 1981 Indian epidemic of acute haemorrhagic conjunctivitis. , 1981, Lancet.

[108]  A. Levey,et al.  Activation of the genetically defined m1 muscarinic receptor potentiates N-methyl-D-aspartate (NMDA) receptor currents in hippocampal pyramidal cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[109]  C. Hanstock,et al.  3-T proton MRS investigation of glutamate and glutamine in adolescents at high genetic risk for schizophrenia. , 2004, The American journal of psychiatry.

[110]  John Suckling,et al.  For personal use. Only reproduce with permission from The Lancet Publishing Group. Kidney transplantation with rabbit antithymocyte globulin induction and sirolimus monotherapy , 2002 .

[111]  T. Sejnowski,et al.  Simulations of cortical pyramidal neurons synchronized by inhibitory interneurons. , 1991, Journal of neurophysiology.

[112]  N. Craddock,et al.  The genetics of schizophrenia and bipolar disorder: dissecting psychosis , 2005, Journal of Medical Genetics.

[113]  Tao Li,et al.  The genetics of schizophrenia: glutamate not dopamine? , 2003, European journal of pharmacology.

[114]  Paul J. Harrison,et al.  Catechol-o-Methyltransferase, Cognition, and Psychosis: Val158Met and Beyond , 2006, Biological Psychiatry.

[115]  J. Tiihonen,et al.  Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis , 2005, Schizophrenia Research.

[116]  B. Yamamoto,et al.  Dopaminergic and GABAergic modulation of glutamate release from rat subthalamic nucleus efferents to the substantia nigra , 2006, Brain Research.

[117]  S. Gacinovic,et al.  Striatal and temporal cortical D2/D3 receptor occupancy by olanzapine and sertindole in vivo: a [123I]epidepride single photon emission tomography (SPET) study , 2000, Psychopharmacology.

[118]  D J Healy,et al.  Ionotropic glutamate receptor binding and subunit mRNA expression in thalamic nuclei in schizophrenia. , 2000, The American journal of psychiatry.

[119]  D. Javitt Management of negative symptoms of schizophrenia , 2001, Current psychiatry reports.

[120]  J. Lieberman,et al.  Cognitive Development in Schizophrenia: Follow-Back from the First Episode , 2006, Journal of clinical and experimental neuropsychology.

[121]  K. Berridge,et al.  The neural basis of drug craving: An incentive-sensitization theory of addiction , 1993, Brain Research Reviews.

[122]  B. Bogerts,et al.  Schizophrenia and anteroventral thalamic nucleus: selective decrease of parvalbumin-immunoreactive thalamocortical projection neurons , 1998, Psychiatry Research: Neuroimaging.

[123]  G. Reynolds,et al.  Neuronal calcium-binding proteins and schizophrenia , 2002, Schizophrenia Research.

[124]  F. Benes,et al.  Emerging principles of altered neural circuitry in schizophrenia , 2000, Brain Research Reviews.

[125]  J. Krystal,et al.  Impact of Schizophrenia and Chronic Antipsychotic Treatment on [123I]CNS-1261 Binding to N-Methyl-D-Aspartate Receptors In Vivo , 2005, Biological Psychiatry.

[126]  K. Erlandsson,et al.  Ketamine displaces the novel NMDA receptor SPET probe [(123)I]CNS-1261 in humans in vivo. , 2006, Nuclear medicine and biology.

[127]  Ravi S. Menon,et al.  Glutamate and glutamine measured with 4.0 T proton MRS in never-treated patients with schizophrenia and healthy volunteers. , 2002, The American journal of psychiatry.

[128]  P. Jeffrey Conn,et al.  N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-d-aspartate receptor activity , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[129]  P. Illés,et al.  D1 but not D2 dopamine receptors or adrenoceptors mediate dopamine-induced potentiation of N-methyl-d-aspartate currents in the rat prefrontal cortex , 2004, Neuroscience Letters.

[130]  Eve C. Johnstone,et al.  Voxel-based morphometry of patients with schizophrenia or bipolar disorder and their unaffected relatives , 2004, Biological Psychiatry.

[131]  C. Ikonomidou,et al.  Hypobaric-ischemic conditions produce glutamate-like cytopathology in infant rat brain , 1989, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[132]  B. Dean,et al.  The binding of [3H]AF-DX 384 is reduced in the caudate-putamen of subjects with schizophrenia. , 1999, Life sciences.

[133]  Jürgen Gallinat,et al.  Glutamate concentrations in human brain using single voxel proton magnetic resonance spectroscopy at 3 Tesla , 2004, NeuroImage.

[134]  Robin M. Murray,et al.  Environmental risk factors for psychosis , 2005, Dialogues in clinical neuroscience.

[135]  S. Sombati,et al.  Cellular Actions of Topiramate: Blockade of Kainate‐Evoked Inward Currents in Cultured Hippocampal Neurons , 2000, Epilepsia.

[136]  S. Kapur Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. , 2003, The American journal of psychiatry.

[137]  Karl J. Friston,et al.  Synaptic Plasticity and Dysconnection in Schizophrenia , 2006, Biological Psychiatry.

[138]  Paul J. Harrison,et al.  Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence , 2005, Molecular Psychiatry.

[139]  Paul J. Harrison,et al.  Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence , 2005, Molecular Psychiatry.

[140]  S. Ögren,et al.  Phencyclidine- and Dizocilpine-Induced Hyperlocomotion Are Differentially Mediated , 1994, Neuropsychopharmacology.

[141]  L. K. Srivastava,et al.  Alterations in dendritic morphology of prefrontal cortical and nucleus accumbens neurons in post-pubertal rats after neonatal excitotoxic lesions of the ventral hippocampus , 2005, Neuroscience.

[142]  U. Heresco-Levy Glutamatergic neurotransmission modulation and the mechanisms of antipsychotic atypicality , 2003, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[143]  J. Meador-Woodruff,et al.  Thalamic dysfunction in schizophrenia: neurochemical, neuropathological, and in vivo imaging abnormalities , 2004, Schizophrenia Research.

[144]  A. Giannini,et al.  Acute ketamine intoxication treated by haloperidol: a preliminary study. , 2000, American journal of therapeutics.

[145]  Akira Sawa,et al.  Schizophrenia: Diverse Approaches to a Complex Disease , 2002, Science.

[146]  J. Seibyl,et al.  Brain SPECT imaging of amphetamine-induced dopamine release in euthymic bipolar disorder patients. , 2000, The American journal of psychiatry.

[147]  B. Kolachana,et al.  Catechol-O-Methyltransferase Genotype and Dopamine Regulation in the Human Brain , 2003, The Journal of Neuroscience.

[148]  M. Giannini,et al.  Comparison of Haloperidol and Chlorpromazine in the Treatment of Phencyclidine Psychosis , 1984, Journal of clinical pharmacology.

[149]  L. Iversen,et al.  DOPAMINE RECEPTORS AND SCHIZOPHRENIA: DRUG EFFECT OR ILLNESS? , 1980, The Lancet.

[150]  W T Carpenter,et al.  Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome. , 1998, The American journal of psychiatry.

[151]  R. Nussbaum,et al.  Midbrain dopamine and prefrontal function in humans: interaction and modulation by COMT genotype , 2005, Nature Neuroscience.

[152]  M. Egan,et al.  Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain. , 2004, American journal of human genetics.

[153]  J. Hietala,et al.  Presynaptic dopamine function in striatum of neuroleptic-naive schizophrenic patients , 1995, The Lancet.

[154]  Eve C Johnstone,et al.  Magnetic resonance imaging of brain in people at high risk of developing schizophrenia , 1999, The Lancet.

[155]  A. Lawrence,et al.  Presynaptic dopaminergic dysfunction in schizophrenia: a positron emission tomographic [18F]fluorodopa study. , 2004, Archives of general psychiatry.

[156]  J. Krystal,et al.  Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. , 1998, The American journal of psychiatry.

[157]  Daniel R. Weinberger,et al.  Neuregulin 1 Transcripts Are Differentially Expressed in Schizophrenia and Regulated by 5′ SNPs Associated With the Disease , 2006 .

[158]  S. Kapur,et al.  Half a century of antipsychotics and still a central role for dopamine D2 receptors , 2003, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[159]  P. Seeman,et al.  Dopamine agonist action of phencyclidine , 2005, Synapse.

[160]  D. Lorrain,et al.  Effects of ketamine and n-methyl-d-aspartate on glutamate and dopamine release in the rat prefrontal cortex: modulation by a group II selective metabotropic glutamate receptor agonist LY379268 , 2003, Neuroscience.

[161]  G. Rosenbaum,et al.  Comparison of sernyl with other drugs: simulation of schizophrenic performance with sernyl, LSD-25, and amobarbital (amytal) sodium; I. Attention, motor function, and proprioception. , 1959, A.M.A. archives of general psychiatry.

[162]  D. Peters,et al.  Xanomeline and the antipsychotic potential of muscarinic receptor subtype selective agonists. , 2006, CNS drug reviews.

[163]  K. Erlandsson,et al.  Optimizing Limbic Selective D2/D3 Receptor Occupancy by Risperidone: A [123I]-Epidepride SPET Study , 2003, Journal of clinical psychopharmacology.

[164]  G. Rosenbaum,et al.  Comparison of phencyclidine hydrochloride (Sernyl) with other drugs. Simulation of schizophrenic performance with phencyclidine hydrochloride (Sernyl), lysergic acid diethylamide (LSD-25), and amobarbital (Amytal) sodium; II. Symbolic and sequential thinking. , 1962, Archives of general psychiatry.

[165]  Franz X Vollenweider,et al.  A systems model of altered consciousness: integrating natural and drug-induced psychoses , 2001, Brain Research Bulletin.

[166]  J. Walecki,et al.  The effect of risperidone on metabolite measures in the frontal lobe, temporal lobe, and thalamus in schizophrenic patients. A proton magnetic resonance spectroscopy (1H MRS). , 2005, Pharmacopsychiatry.